NIH-supported clinical trial of phage therapy for cystic fibrosis begins
11 October 2022
Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs. The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers. The trial is being conducted by the Antibacterial Resistance Leadership Group (ARLG)(link is external), funded by the National Institute of Allergy and Infectious Diseases. Investigators aim to enroll up to 72 adults at 16 CF centers across the United States.
Further reading: National Institutes of Health
Author(s): National Institutes of Health
Healthy Patients Smart Innovations
Ambassador Network
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!